Table 5. Phase III trials of multidrug combinations incorporating newer agents in the treatment of advance NSCLC.

New agent	First author	Patients (n)	Chemotherapy regimens	Response rates (%)	Median survival weeks
Vinorelbine	Le Chevalier et al., 2001 (23)	412	Vinorelbine	14	36
			Vinorelbine, cisplatin	30*	43*
	Depierre (24)	231	Vinorelbine	16	32
			Vinorelbine, cisplatin	43*	33
	Baldini et al., 1998 (25)	140	Vinorelbine, carboplatin	14	34
			Vinorelbine, cisplatin, ifosfamide	17	38
			Cisplatin, vindesine, mitomycin	14	36
	Wozniak (26)	432	Cisplatin	12	26
			Vinorelbine, cisplatin	26	35
	Frasci (27)	120	Vinorelbine	15	18
			Vinorelbine, gemcitabine	22	29
Paclitaxel/Docetaxel	Kelly et al., 2001 (28)	406	Vinorelbine, cisplatin	28	32
			Paclitaxel, carboplatin	24	34
	Giaccone (29)	332	Paclitaxel 175, cisplatin	44	41
			Cisplatin, teniposite	30	42
	Gatzemeier (30)	414	Cisplatin 100	17	37
			Paclitaxel 175, cisplatin 80	26*	35
	Bonomi (31)	599	Paclitaxel 250, cisplatin	28*	44*
			Paclitaxel 135, cisplatin	25*	41*
			Cisplatin, etoposide	12	33
	Schiller et al., 2002 (32)	1,207	Cisplatin, paclitaxel	21	32
			Cisplatin, gemcitabine	22	30
			Cisplatin, docetaxel	17	32
			Carboplatin, paclitaxel	17	32
	Georgoulias et al. (33)	302	Docetaxel, cisplatin	36*	52
			Docetaxel	18	40
	Stathopoulos et al. (34)	360	Paclitaxel, vinorelbine	46	44
			Paclitaxel, carboplatin	43	40
Gemcitabine	Crino (35)	307	Gemcitabine, cisplatin	38*	37
			Cisplatin, mitomycin, ifosfamide (MIC)	26	42
	Cardenal (36)	135	Gemcitabine, cisplatin	41*	38*
			Cisplatin, etoposide	22	31
	Sander (37)	522	Cisplatin	11	33
			Gemcitabine, cisplatin	30*	38
	Comella et al. (38)	180	Gemcitabine, cisplain, vinorelbine	47*	51*
			Gemcitabine, cisplatin	30	42*
			Cisplatin, vinorelbine	25	35
Irinotecan (CPT-11)	Masuda (39)	398	Cisplatin 80, irinotecan 60	43	50
			Cisplatin 80, vindesine	31	47
			Irinotecan 100	21	46
	Negoro (40)	398	Irinotecan, cisplatin	44	50
			Cisplatin, vindesine	32	46
			Irinotecan	21	46
Pemetrexed	Scaglioti et al. (41)	1,725	Cisplatin, pemetrexed	31	40
			Cisplatin, gemcitabine	28	40

NR, not reported; NS, not significant; *, P<0.05.